Numab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for Multispecific Antibody NM81 in Inflammatory Bowel Disease (IBD)

Kaken Pharmaceutical in-licenses NM81 across select Asian territories and commits to funding global development into the clinicHORGEN, Switzerland and TOKYO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Numab ...

Will Sharply Reduced Net Losses Signal a Turning Point for Xencor's (XNCR) Path to Profitability?

Xencor, Inc. reported its third quarter and nine-month 2025 financial results on November 5, showing net loss reductions to US$6.03 million and US$85.27 million, respectively, both significantly lower ...
Investor's Business Daily on MSN

Coal Stocks Pare Gains Amid The Rare Earths Craze

Stocks for some coal companies are up 200% this year, as investors hope they'll reinvent themselves as rare earth miners.
BMJ Open

Quality assessment of irritable bowel syndrome-related medical information on major video platforms in China: a cross-sectional study

Objective In China, a large number of health-related short videos are posted on video platforms, including educational videos ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2025 Earnings Call Transcript

Q3 2025 Earnings Call Transcript November 4, 2025 Rigel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1 ...
Santé log

TREMFYA® (guselkumab) receives European Commission approval for subcutaneous induction through to maintenance in adults with ulcerative colitis, now the first IL-23 inhibitor ...

“With today’s approval, guselkumab is the first IL-23 inhibitor to offer inflammatory bowel disease patients robust clinical and endoscopic results with a fully subcutaneous induction dose regimen, ...